Evidence map›Paper›PMID 38987568›Full record

ArticleBone research2024

Caspase-8 promotes scramblase-mediated phosphatidylserine exposure and fusion of osteoclast precursors.

Brenda Krishnacoumar, Martin Stenzel, Hilal Garibagaoglu, Yasunori Omata, Rachel L Sworn, Thea Hofmann, Natacha Ipseiz, Magdalena A Czubala, Ulrike Steffen, Antonio Maccataio and 11 more

Abstract read
In one paragraph

Article in Bone research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Cell fusion in osteoclastogenesis.Biochemical Society transactions · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Cell-cell fusion: To lose one life and begin another.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025
    Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Brenda KrishnacoumarDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany. Brenda.Krishnacoumar@uk-essen.de.
Martin StenzelDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Hilal GaribagaogluDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.ORCID http://orcid.org/0000-0001-7673-7330
Yasunori OmataDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Rachel L SwornDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Thea HofmannDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Natacha IpseizSystems Immunity Research Institute, Heath Park, Cardiff University, Cardiff, CF14 4XN, UK.
Magdalena A CzubalaSystems Immunity Research Institute, Heath Park, Cardiff University, Cardiff, CF14 4XN, UK.ORCID http://orcid.org/0000-0001-9881-1095
Ulrike SteffenDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Antonio MaccataioDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Cornelia StollDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Christina BöhmDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Martin HerrmannDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.ORCID http://orcid.org/0000-0002-0258-2484
Stefan UderhardtDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
Robert H JenkinsDivision of Infection & Immunity, Heath Park, Cardiff University, Cardiff, CF14 4XN, UK.
Philip R TaylorSystems Immunity Research Institute, Heath Park, Cardiff University, Cardiff, CF14 4XN, UK.
Anika GrüneboomDepartment of Biopsectroscopy, Leibniz Institut für Analytische Wissenschaften-ISAS-e.V., Bunsen-Kirchhoff-Str. 11, Dortmund, 44227, Germany.ORCID http://orcid.org/0000-0002-7928-5613
Mario M ZaissDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.ORCID http://orcid.org/0000-0003-3844-1664
Georg SchettDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.ORCID http://orcid.org/0000-0001-8740-9615
Gerhard KrönkeDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.ORCID http://orcid.org/0000-0002-7566-4325
Carina ScholtysekDepartment of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, 91054, Erlangen, Germany. carina.scholtysek@uk-erlangen.de.

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) SCHE 2062/1-1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) (BB/T009543/1Wellcome TrustWellcome Trust (Wellcome) 107964/Z/15/Z
6 · The paper itself

Abstract

Efficient cellular fusion of mononuclear precursors is the prerequisite for the generation of fully functional multinucleated bone-resorbing osteoclasts. However, the exact molecular factors and mechanisms controlling osteoclast fusion remain incompletely understood. Here we identify RANKL-mediated activation of caspase-8 as early key event during osteoclast fusion. Single cell RNA sequencing-based analyses suggested that activation of parts of the apoptotic machinery accompanied the differentiation of osteoclast precursors into mature multinucleated osteoclasts. A subsequent characterization of osteoclast precursors confirmed that RANKL-mediated activation of caspase-8 promoted the non-apoptotic cleavage and activation of downstream effector caspases that translocated to the plasma membrane where they triggered activation of the phospholipid scramblase Xkr8. Xkr8-mediated exposure of phosphatidylserine, in turn, aided cellular fusion of osteoclast precursors and thereby allowed generation of functional multinucleated osteoclast syncytia and initiation of bone resorption. Pharmacological blockage or genetic deletion of caspase-8 accordingly interfered with fusion of osteoclasts and bone resorption resulting in increased bone mass in mice carrying a conditional deletion of caspase-8 in mononuclear osteoclast precursors. These data identify a novel pathway controlling osteoclast biology and bone turnover with the potential to serve as target for therapeutic intervention during diseases characterized by pathologic osteoclast-mediated bone loss. Proposed model of osteoclast fusion regulated by caspase-8 activation and PS exposure. RANK/RANK-L interaction. Activation of procaspase-8 into caspase-8. Caspase-8 activates caspase-3. Active capase-3 cleaves Xkr8. Local PS exposure is induced. Exposed PS is recognized by the fusion partner. FUSION. PS is re-internalized.

Indexed as

Caspase 8Cell FusionOsteoclastsPhosphatidylserinesPhospholipid Transfer ProteinsAnimalsBone ResorptionCell DifferentiationMiceMice, Inbred C57BLRANK LigandCaspase 8PhosphatidylserinesPhospholipid Transfer ProteinsRANK Ligand

Identifiers

PMID38987568
PMCPMC11237014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.